Israel Lowy

Nivolumab plus Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan et al. · New England Journal of Medicine · 2013 · 4.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Julie R. Brahmer, Charles G. Drake, Ira Wollner et al. · Journal of Clinical Oncology · 2010 · 2.9K citations · Full text

Medicine, Oncology, Pharmacology +17

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Michael R. Migden, Danny Rischin, Chrysalyne D. Schmults et al. · New England Journal of Medicine · 2018 · 1.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Richard E. Royal, Catherine Lévy, Keli Turner et al. · Journal of Immunotherapy · 2010 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +14

Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4

Kimberly E Beck, Joseph Blansfield, Khoi Q. Tran et al. · Journal of Clinical Oncology · 2006 · 834 citations · Full text

Life Sciences, Immunology, Oncology +17